Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
Citi Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
May 29, 2024 12:57 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $48.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
The analyst comments "Its always tough to draw conclusions from such small data sets (N=4) and ever more so in an open-label, uncontrolled setting, where the... More



